I think that's what happening with the DCF models that the Analysts covering Neuren are using. They are inputting what are reasonable numbers but the outcome is so far from the reality of the current share price that they either figure they've made an error or, more likely, won't risk the reputational damage of publishing, what appears at first blush, to be nonsense. The 'rubber band' of professional confidence stretches with age, but it always has its limits. Breaking that, with what appears outlandish numbers risks too much, for many. Fundamentals it seems, has to 'catch up' up to their modelling, to prove what was there in the first place. Perhaps that is a foundation for why the general investor always seems shocked that the regular 100%+ premiums paid in biotech M&A?
Hot Copper 'analysts' will give you fearless predictions, the question is: do you dare to believe them? What does the history of who has been more correct in these SP targets of the past, say, two years, signal for the future?
NEU Price at posting:
$23.33 Sentiment: Buy Disclosure: Held
(20min delay)